These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9372889)

  • 1. Immunologic findings in Peyronie's disease: a controlled study.
    Schiavino D; Sasso F; Nucera E; Alcini E; Gulino G; Milani A; Patriarca G
    Urology; 1997 Nov; 50(5):764-8. PubMed ID: 9372889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there any association between Peyronie's disease and serum collagen markers?
    Rhoden EL; Buselato LG; Ting HY; Telöken C; Souto CA
    Int J Impot Res; 2000 Dec; 12(6):302-4. PubMed ID: 11416832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunological features of Peyronie's disease.
    Ralph DJ; Mirakian R; Pryor JP; Bottazzo GF
    J Urol; 1996 Jan; 155(1):159-62. PubMed ID: 7490821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology.
    Nachtsheim DA; Rearden A
    J Urol; 1996 Oct; 156(4):1330-4. PubMed ID: 8808864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-1-antitrypsin levels and genetic variation of the alpha-1-antitrypsin gene in Peyronie's disease.
    Hauck EW; Hauptmann A; Haag SM; Bohnert A; Weidner W; Bein G; Hackstein H
    Eur Urol; 2004 Nov; 46(5):623-8; discussion 628. PubMed ID: 15474273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease.
    Haag SM; Hauck EW; Szardening-Kirchner C; Diemer T; Cha ES; Weidner W; Eickelberg O
    Eur Urol; 2007 Jan; 51(1):255-61. PubMed ID: 16782264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there an immunogenetic basis for Peyronie's disease?
    Leffell MS
    J Urol; 1997 Jan; 157(1):295-7. PubMed ID: 8976283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: results of a prospective approach.
    Hauck EW; Hauptmann A; Bschleipfer T; Schmelz HU; Altinkilic BM; Weidner W
    J Urol; 2004 Jan; 171(1):296-9. PubMed ID: 14665898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroandrologic considerations in impotent patients with Peyronie's disease].
    Salinas Casado J; Vírseda Chamorro M; Samblás García R; Esteban Fuertes M; Aristizábal Agudelo JM; Delgado Marín JA; Blázquez Izquierdo J; Resel Estévez L
    Arch Esp Urol; 1997; 50(6):695-9. PubMed ID: 9412372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetic and bacteriological aspects of Peyronie's disease.
    Ralph DJ; Schwartz G; Moore W; Pryor JP; Ebringer A; Bottazzo GF
    J Urol; 1997 Jan; 157(1):291-4. PubMed ID: 8976282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective analysis of 16S rDNA as a highly sensitive marker for bacterial presence in Peyronie's disease plaques.
    Hauck EW; Domann E; Hauptmann A; Weidner W; Chakraborty T; Hossain HM
    J Urol; 2003 Nov; 170(5):2053-6. PubMed ID: 14532852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Peyronie's disease--a review.
    Tunuguntla HS
    World J Urol; 2001 Aug; 19(4):244-50. PubMed ID: 11550782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective?
    Carson CC
    Tech Urol; 1997; 3(3):135-9. PubMed ID: 9422444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of the use of propoleum in Peyronie's disease].
    Lemourt Oliva M; Filgueiras López E; Rodríguez Barroso A; González Oramas E; Bordonado R
    Arch Esp Urol; 1998 Mar; 51(2):171-6. PubMed ID: 9586317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic fibroblast growth factor expression in Peyronie's disease.
    Mulhall JP; Thom J; Lubrano T; Shankey TV
    J Urol; 2001 Feb; 165(2):419-23. PubMed ID: 11176387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peyronie's disease: a review.
    Gholami SS; Gonzalez-Cadavid NF; Lin CS; Rajfer J; Lue TF
    J Urol; 2003 Apr; 169(4):1234-41. PubMed ID: 12629334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iontophoresis for treatment of Peyronie's disease.
    Riedl CR; Plas E; Engelhardt P; Daha K; Pflüger H
    J Urol; 2000 Jan; 163(1):95-9. PubMed ID: 10604323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peyronie's disease in men with HIV responding to highly active antiretroviral therapy.
    Rogers GD; French MA
    HIV Med; 2004 May; 5(3):185-6. PubMed ID: 15139986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peyronie's disease in diabetic patients being screened for erectile dysfunction.
    El-Sakka AI; Tayeb KA
    J Urol; 2005 Sep; 174(3):1026-30. PubMed ID: 16094040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peyronie's disease and peripheral neuropathies].
    Diagne M; Gueye SM; Ba M; Konan PG; Diop AG; Ndiaye MM; Ndiaye IP; Mensah A
    Dakar Med; 1998; 43(2):234-7. PubMed ID: 10797972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.